These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 1325427)

  • 41. Autocrine stimulatory mechanism by transforming growth factor beta in human hepatocellular carcinoma.
    Matsuzaki K; Date M; Furukawa F; Tahashi Y; Matsushita M; Sakitani K; Yamashiki N; Seki T; Saito H; Nishizawa M; Fujisawa J; Inoue K
    Cancer Res; 2000 Mar; 60(5):1394-402. PubMed ID: 10728705
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The gene expression level of transforming growth factor-beta (TGF-beta) as a biological prognostic marker of hepatocellular carcinoma.
    Ikeguchi M; Iwamoto A; Taniguchi K; Katano K; Hirooka Y
    J Exp Clin Cancer Res; 2005 Sep; 24(3):415-21. PubMed ID: 16270528
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differential effects of transforming growth factor-beta 1 and bone morphogenetic proteins in cultured rat osteogenic sarcoma and mink lung epithelial cells.
    Kim GY; Lee HH; Cho SW
    Biochem Mol Biol Int; 1994 May; 33(2):253-61. PubMed ID: 7951046
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of transforming growth factor alpha and vascular endothelial growth factor in diagnosis of hepatocellular carcinoma.
    El-Sherif WT; Makhlouf NA; El-Gendi SS; Hassan HI; Herdan OM
    Egypt J Immunol; 2012; 19(2):53-65. PubMed ID: 23885407
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hepatitis B virus X protein shifts human hepatic transforming growth factor (TGF)-beta signaling from tumor suppression to oncogenesis in early chronic hepatitis B.
    Murata M; Matsuzaki K; Yoshida K; Sekimoto G; Tahashi Y; Mori S; Uemura Y; Sakaida N; Fujisawa J; Seki T; Kobayashi K; Yokote K; Koike K; Okazaki K
    Hepatology; 2009 Apr; 49(4):1203-17. PubMed ID: 19263472
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Elevated plasma TGF-beta1 levels correlate with decreased survival of metastatic breast cancer patients.
    Ivanović V; Demajo M; Krtolica K; Krajnović M; Konstantinović M; Baltić V; Prtenjak G; Stojiljković B; Breberina M; Nesković-Konstantinović Z; Nikolić-Vukosavljević D; Dimitrijević B
    Clin Chim Acta; 2006 Sep; 371(1-2):191-3. PubMed ID: 16650397
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Expression of transforming growth factor-beta 1 in hepatocellular carcinoma in comparison with the non-tumor tissue.
    Idobe Y; Murawaki Y; Kitamura Y; Kawasaki H
    Hepatogastroenterology; 2003; 50(49):54-9. PubMed ID: 12629989
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Transforming Growth Factor β is a Poor Prognostic Factor and Inhibits the Favorable Prognostic Value of CD8+ CTL in Human Hepatocellular Carcinoma.
    Huang CY; Wang H; Liao W; Han F; Li YQ; Chen SW; Lao XM
    J Immunother; 2017 Jun; 40(5):175-186. PubMed ID: 28394813
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Laminin-5 with transforming growth factor-beta1 induces epithelial to mesenchymal transition in hepatocellular carcinoma.
    Giannelli G; Bergamini C; Fransvea E; Sgarra C; Antonaci S
    Gastroenterology; 2005 Nov; 129(5):1375-83. PubMed ID: 16285938
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma.
    Zhang H; Ye QH; Ren N; Zhao L; Wang YF; Wu X; Sun HC; Wang L; Zhang BH; Liu YK; Tang ZY; Qin LX
    J Cancer Res Clin Oncol; 2006 Nov; 132(11):709-17. PubMed ID: 16786357
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Activation of the transforming growth factor-β/SMAD transcriptional pathway underlies a novel tumor-promoting role of sulfatase 1 in hepatocellular carcinoma.
    Dhanasekaran R; Nakamura I; Hu C; Chen G; Oseini AM; Seven ES; Miamen AG; Moser CD; Zhou W; van Kuppevelt TH; van Deursen JM; Mounajjed T; Fernandez-Zapico ME; Roberts LR
    Hepatology; 2015 Apr; 61(4):1269-83. PubMed ID: 25503294
    [TBL] [Abstract][Full Text] [Related]  

  • 52. EVI1, a target gene for amplification at 3q26, antagonizes transforming growth factor-β-mediated growth inhibition in hepatocellular carcinoma.
    Yasui K; Konishi C; Gen Y; Endo M; Dohi O; Tomie A; Kitaichi T; Yamada N; Iwai N; Nishikawa T; Yamaguchi K; Moriguchi M; Sumida Y; Mitsuyoshi H; Tanaka S; Arii S; Itoh Y
    Cancer Sci; 2015 Jul; 106(7):929-37. PubMed ID: 25959919
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level.
    Li X; Feng GS; Zheng CS; Zhuo CK; Liu X
    World J Gastroenterol; 2004 Oct; 10(19):2878-82. PubMed ID: 15334691
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association of serum level of growth differentiation factor 15 with liver cirrhosis and hepatocellular carcinoma.
    Liu X; Chi X; Gong Q; Gao L; Niu Y; Chi X; Cheng M; Si Y; Wang M; Zhong J; Niu J; Yang W
    PLoS One; 2015; 10(5):e0127518. PubMed ID: 25996938
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy.
    Shariat SF; Shalev M; Menesses-Diaz A; Kim IY; Kattan MW; Wheeler TM; Slawin KM
    J Clin Oncol; 2001 Jun; 19(11):2856-64. PubMed ID: 11387358
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reduced expression of transcriptional intermediary factor 1 gamma promotes metastasis and indicates poor prognosis of hepatocellular carcinoma.
    Ding ZY; Jin GN; Wang W; Chen WX; Wu YH; Ai X; Chen L; Zhang WG; Liang HF; Laurence A; Zhang MZ; Datta PK; Zhang B; Chen XP
    Hepatology; 2014 Nov; 60(5):1620-36. PubMed ID: 24954480
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High plasma concentrations of endothelin-like immunoreactivities in patients with hepatocellular carcinoma.
    Nakamuta M; Ohashi M; Tabata S; Tanabe Y; Goto K; Naruse M; Naruse K; Hiroshige K; Nawata H
    Am J Gastroenterol; 1993 Feb; 88(2):248-52. PubMed ID: 8380950
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Validity of plasma macrophage migration inhibitory factor for diagnosis and prognosis of hepatocellular carcinoma.
    Zhao YM; Wang L; Dai Z; Wang DD; Hei ZY; Zhang N; Fu XT; Wang XL; Zhang SC; Qin LX; Tang ZY; Zhou J; Fan J
    Int J Cancer; 2011 Nov; 129(10):2463-72. PubMed ID: 21213214
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of Mesenchymal Stem Cells and Vitamin D on Transforming Growth Factor Beta Signaling Pathway in Hepatocellular Carcinoma in Rats.
    Saad El-Din S; Fouad H; Rashed LA; Mahfouz S; Hussein RE
    Asian Pac J Cancer Prev; 2018 Apr; 19(4):905-912. PubMed ID: 29693337
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Insulin-like growth factor binding protein-2 mediates the inhibition of DNA synthesis by transforming growth factor-beta in mink lung epithelial cells.
    Dong F; Wu HB; Hong J; Rechler MM
    J Cell Physiol; 2002 Jan; 190(1):63-73. PubMed ID: 11807812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.